MedPath

云南药科院生物医药股份有限公司

Ownership
-
Established
2022-07-07
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

8

NMPA:8

Drug Approvals

Lidocaine Hydrochloride Injection

Product Name
盐酸利多卡因注射液
Approval Number
国药准字H20254100
Approval Date
May 13, 2025
NMPA

Magnesium Sulfate Injection

Product Name
硫酸镁注射液
Approval Number
国药准字H20254005
Approval Date
Apr 22, 2025
NMPA

Furosemide Injection

Product Name
呋塞米注射液
Approval Number
国药准字H20253555
Approval Date
Mar 4, 2025
NMPA

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20253218
Approval Date
Jan 14, 2025
NMPA

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20244763
Approval Date
Aug 27, 2024
NMPA

Tranexamic Acid Injection

Product Name
氨甲环酸注射液
Approval Number
国药准字H20244247
Approval Date
Jun 28, 2024
NMPA

Tranexamic Acid Injection

Product Name
氨甲环酸注射液
Approval Number
国药准字H20244246
Approval Date
Jun 28, 2024
NMPA

Tranexamic Acid Injection

Product Name
氨甲环酸注射液
Approval Number
国药准字H20244245
Approval Date
Jun 28, 2024
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.